Desensitization allows successful transplantation of patients with a positive crossmatch (PXM) against their live donor. We evaluated outcomes following PXM renal transplant despite failure to convert to negative flow cytometric crossmatch (FCXM) after desensitization. Patients that underwent desensitization before PXM transplant between 1/1/00 and 11/1/11 were identified for analysis. Patients who received a transplant despite failure to convert to negative FCXM were identified as the not converted group. Patients who converted to negative FCXM after desensitization comprised the converted group control arm. 108 patients were desensitized before PXM transplant, (not converted group=42; converted group=66). Mean eGFR was comparable between ...
BACKGROUND: Traditionally, the presence of antibodies against human leukocyte antigen (HLA)-C and DP...
BACKGROUND: Despite the obvious survival benefit compared to that among waitlist patients, outcome...
INTRODUCTION: The number of end-stage renal disease (ESRD) patients with preformed antibodies waitin...
Pretransplantation crossmatching is an integral part of kidney transplantation. Flow cytometric cros...
Methods of crossmatch testing prior to kidney transplantation are not standardized and there are lim...
Desensitization regimens including use of intravenous immune globulin and rituximab have been report...
Background/PurposeDesensitization regimens including use of intravenous immune globulin and rituxima...
Background. High-dose IVIG (2 g/kg) alone or low-dose IVIG (100 mg/kg) in conjunction with plasma ex...
Recently, Luminex-crossmatch (LumXm) was introduced. The aim of this study was to evaluate clinical ...
Sensitized patients may reject renal transplants at a tempo or with a force dictated by their previo...
A successful transplantation, across a positive crossmatch barrier, is one of the most persistent lo...
This prospective, blinded observational study was conducted to measure the predictive value the of f...
none6On all kidney waiting lists the 10% to 20% of patients who have antibodies against more than 80...
RATIONALE: Human leukocyte antigen (HLA) is the major immunologic barrier in kidney transplantatio...
Desensitization protocols reduce donor-specific anti-HLA antibodies (DSA) and enable renal transplan...
BACKGROUND: Traditionally, the presence of antibodies against human leukocyte antigen (HLA)-C and DP...
BACKGROUND: Despite the obvious survival benefit compared to that among waitlist patients, outcome...
INTRODUCTION: The number of end-stage renal disease (ESRD) patients with preformed antibodies waitin...
Pretransplantation crossmatching is an integral part of kidney transplantation. Flow cytometric cros...
Methods of crossmatch testing prior to kidney transplantation are not standardized and there are lim...
Desensitization regimens including use of intravenous immune globulin and rituximab have been report...
Background/PurposeDesensitization regimens including use of intravenous immune globulin and rituxima...
Background. High-dose IVIG (2 g/kg) alone or low-dose IVIG (100 mg/kg) in conjunction with plasma ex...
Recently, Luminex-crossmatch (LumXm) was introduced. The aim of this study was to evaluate clinical ...
Sensitized patients may reject renal transplants at a tempo or with a force dictated by their previo...
A successful transplantation, across a positive crossmatch barrier, is one of the most persistent lo...
This prospective, blinded observational study was conducted to measure the predictive value the of f...
none6On all kidney waiting lists the 10% to 20% of patients who have antibodies against more than 80...
RATIONALE: Human leukocyte antigen (HLA) is the major immunologic barrier in kidney transplantatio...
Desensitization protocols reduce donor-specific anti-HLA antibodies (DSA) and enable renal transplan...
BACKGROUND: Traditionally, the presence of antibodies against human leukocyte antigen (HLA)-C and DP...
BACKGROUND: Despite the obvious survival benefit compared to that among waitlist patients, outcome...
INTRODUCTION: The number of end-stage renal disease (ESRD) patients with preformed antibodies waitin...